Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN74215569
ISRCTN74215569
Completed
Not Applicable

A phase 3 study to determine the efficacy and safety of recombinant human activated protein C in severe sepsis

Eli Lilly and Company (USA)0 sites1,690 target enrollmentJanuary 7, 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSevere sepsisInfections and InfestationsSepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Severe sepsis
Sponsor
Eli Lilly and Company (USA)
Enrollment
1690
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 7, 2004
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Eli Lilly and Company (USA)

Eligibility Criteria

Inclusion Criteria

  • •Not provided at time of registration

Exclusion Criteria

  • •Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
A study to learn more about asundexian for prevention of stroke in male and female participants who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptoms.Health Condition 1: I699- Sequelae of unspecified cerebrovascular diseases
CTRI/2024/01/061517Bayer Pharmaceuticals Private Limited
Suspended
Phase 3
A phase III sTudy evaluating the efficacy and safety of Trans-Esophageal Motor-evoked PoTential monitoring and the special electrode during aortic surgerypatients undergoing aortic surgery carrying the risk of ischemic spinal cord injuryischemic spinal cord injury, aortic aneurysm, aortic dissectionD001018
JPRN-jRCT2042230116orihiko Shiiya100
Active, not recruiting
Phase 1
Phase 3 study to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancerMetastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-005611-46-SETavanta Therapeutics, Inc.108
Active, not recruiting
Phase 1
Phase 3 study to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancerMetastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-005611-46-HUTavanta Therapeutics, Inc.108
Active, not recruiting
Phase 1
Phase 3 study to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancerMetastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-005611-46-ESTavanta Therapeutics, Inc.108